Cipla, Sun Pharma, Ipca Labs, JB Pharma boost Indian pharma growth in March

The Indian Pharma Market (IPM) created a conducive growth environment in 2025 for March at 9.3% YoY, which shows a remarkable recovery from the months gone by. Key growth drivers included Cipla...

Glenmark, Sun Pharma, Zydus recall medicines in US over manufacturing issues

According to recent information collected from the U.S. Food and Drug Administration (FDA), major leading pharmaceutical firms in India are recalling...

CRISPR technology identifies crucial genes linked to Parkinson's disease

Researchers in the US have utilized advanced CRISPR interference technology to discover a new collection of genes that enhance the likelihood of developing Parkinson's disease...

3RD Annual Pharma Impurities Conclave 2025

With the increasing scrutiny on drug safety and efficacy, understanding impurities is more important than ever and ever evolving guidelines are not aiding the efforts. To address those lacunas, Eminence has come up with 3rd Annual Pharma Impurity Con

Announcing the 4th Edition Drug Safety Symposium 2025

With patient safety becoming more critical than ever in today's evolving healthcare landscape, the demand for robust drug safety practices continues to surge. After several successful editions in India and Dubai, Eminence Group returns with 4th Editi

JNCASR Researchers Develop 6BIO for Autism Spectrum Disorder Treatment

A promising therapeutic option has been proposed at the Jawaharlal Nehru Centre for Advanced Scientific Research for treating...

Cipla Receives USFDA Approval for Generic Cancer Medication

Cipla made significant progress after obtaining USFDA permission for marketing its generic cancer drug. The USFDA granted Cipla authorization to introduce their paclitaxel protein-bound particles for injectable suspension (albumin-bound) under the br

Genetic mutations linked to epilepsy disorder identified.

Researchers believe that they have unearthed a fresh genetic cause of neurodevelopmental disorders that have never before...

Rs 24 lakh worth of faulty medicines recalled in statewide Karnataka crackdown

The Drug Administration Department of Karnataka has withdrawn defective medications totaling Rs 24.3 lakh from the market as part of a campaign against subpar pharmaceuticals.

Novartis unveils $23B US investment in manufacturing and R&D

Novartis is launching its latest investment initiative shortly after President Donald Trump introduced sweeping new tariffs on...

© 2025 India Pharma Outlook. All Rights Reserved.